
New abstracts show the oral PCSK9 inhibitor cut LDL-C by 57% to 63% across PREVENT risk groups, with reductions maintained in an extension study.
Supplements and Featured Publications
over 24 years ago
Participating Facultyover 24 years ago
Clinical Features of Psoriatic Arthritisover 24 years ago
Etanercept: A New Era in the Treatment of Psoriatic Arthritis





